跳至主要内容
临床试验/NCT01607593
NCT01607593已完成不适用

A Retrospective And Multicenter Survey To Investigate The Dosage, Efficacy And Safety Of Sertraline In Posttraumatic Stress Disorder Patients

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.4 个研究点 分布在 1 个国家目标入组 123 人开始时间: 2012年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
123
试验地点
4
主要终点
Clinical Global Impression - Improvement (CGI-I) at End of Administration/Observation

研究概览

简要总结

This is a multicenter retrospective study to investigate the dosage regimens of sertraline in the treatment of Posttraumatic Stress Disorder (PTSD) under current medical practice and the efficacy and safety of this drug in patients with PTSD. Data will be collected from the medical records of patients with PTSD.

详细描述

Patients with PTSD who have been dosed with sertraline from July 2006 (i.e., the start of marketing of this drug in Japan) or later to before contracting with each investigational site.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with PTSD who have been dosed with sertraline since July 2006 or later.
  • Patients must be Japanese.
  • Patients should be started before the conclusion of a contract with each investigational site.

排除标准

  • Not applicable.

研究组 & 干预措施

sertraline (Zoloft)

干预措施: sertraline (Zoloft) (Drug)

结局指标

主要结局

Clinical Global Impression - Improvement (CGI-I) at End of Administration/Observation

时间窗: Up to 6 years

Number of participants in each category of CGI-I at end of administration/observation. CGI-I is a 7-point clinician-rated scale, ranging from (1) Very much improved, (2)Much improved, (3) Minimally improved, (4) No change, (5) Minimally worse, (6) Much worse, and (7) Very much worse.

Clinical Global Impression of Severity (CGI-S) at Start of Administration/Observation

时间窗: Start of administration

Number of participants in each category of CGI-S at start and end of administration/observation. CGI-S is a 7-point clinician-rated scale to assess severity of participant's current illness state, ranging from (1)Normal, not ill at all, (2)Borderline mentally ill, (3)Mildly ill, (4)Moderately ill, (5)Markedly ill, (6)Severely ill, (7)Among the most severely ill.

Clinical Global Impression of Severity (CGI-S) at End of Administration/Observation

时间窗: Up to 6 years

Number of participants in each category of CGI-S at start and end of administration/observation. CGI-S is a 7-point clinician-rated scale to assess severity of participant's current illness state, ranging from (1)Normal, not ill at all, (2)Borderline mentally ill, (3)Mildly ill, (4)Moderately ill, (5)Markedly ill, (6)Severely ill, (7)Among the most severely ill.

次要结局

未报告次要终点

研究者

发起方
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验